US Stock Market Move | Pomegranate Cloud Doctor (POM.US) soared nearly 16%, becoming China's largest platform for follow-up visits for chronic diseases.

On Thursday, the new stock Pomegranate Cloud Medicine (POM.US) surged nearly 16%, closing at $4.67. It is reported that Pomegranate Cloud Medicine was established in 2010 and has business segments including offline pharmacies, online pharmaceutical e-commerce, pharmaceutical distribution, and internet medical services. Its core business is chronic disease follow-up services, making it the largest chronic disease review platform in China. According to Frost & Sullivan data, by 2022 Pomegranate Cloud Medicine ranks sixth in the Chinese internet hospital market in terms of the number of contracted doctors. Its business covers multiple regions nationwide, with a total of more than 214,200 contracted doctors as of December 31, 2024. It has served 699,300 patients and issued about 3.13 million prescriptions. Its core proprietary technology and service model drive the digitization of chronic disease management and pharmaceutical supply chain. Through tools like the "Pomegranate Doctor" doctor management portal and WeChat official account, it facilitates a large number of online consultations and prescription renewal services.